Cargando…
Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies
BACKGROUND: The influence of different non-myeloablative conditioning regimens on clinical outcome remains undefined. MATERIAL/METHODS: We retrospectively analyzed the hematopoietic reconstitution, graft-versus-host disease (GVHD), and quality of life (QOL) in 56 patients with hematologic malignanci...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530985/ https://www.ncbi.nlm.nih.gov/pubmed/26238068 http://dx.doi.org/10.12659/MSM.893846 |
_version_ | 1782384966937608192 |
---|---|
author | Li, Qingshan Meng, Fanyi Zhou, Ming Yu, Bizhen Mo, Wenjian Du, Qinghua Jiang, Xuejie Wei, Yaming |
author_facet | Li, Qingshan Meng, Fanyi Zhou, Ming Yu, Bizhen Mo, Wenjian Du, Qinghua Jiang, Xuejie Wei, Yaming |
author_sort | Li, Qingshan |
collection | PubMed |
description | BACKGROUND: The influence of different non-myeloablative conditioning regimens on clinical outcome remains undefined. MATERIAL/METHODS: We retrospectively analyzed the hematopoietic reconstitution, graft-versus-host disease (GVHD), and quality of life (QOL) in 56 patients with hematologic malignancies who underwent non-myeloablative stem cell transplantation (NST) with a conditioning regimen based on anti-thymocyte globulin (ATG), followed by donor lymphocyte infusion (n=24), or Fludarabine (FLU) (n=32). Hematopoietic stem cells were derived from low-resolution HLA-matched identical sibling donors. RESULTS: The blood type transformation and platelet reconstitution presented significantly earlier in the FLU group than the ATG group (P<0.05). Within 100 days post-transplantation, the incidence of grade I–IV acute GVHD was significantly lower in the ATG group than the FLU group (P<0.05). After 100 days post-transplant, extensive chronic GVHD (cGVHD) was more prevalent in the ATG group than the FLU group (P<0.05). There were lower cumulative risk of relapse and higher non-relapse-related mortality in the ATG group, but better QOL in the FLU group within 24 months, and no difference in 3-year disease-free survival (DFS) or overall survival (OS) between the 2 groups (P>0.05). CONCLUSIONS: The FLU-based conditioning regimen improved hematopoietic reconstitution and decreased extensive cGVHD, but there was no difference in 3-year DFS or OS between the 2 groups. |
format | Online Article Text |
id | pubmed-4530985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45309852015-08-21 Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies Li, Qingshan Meng, Fanyi Zhou, Ming Yu, Bizhen Mo, Wenjian Du, Qinghua Jiang, Xuejie Wei, Yaming Med Sci Monit Clinical Research BACKGROUND: The influence of different non-myeloablative conditioning regimens on clinical outcome remains undefined. MATERIAL/METHODS: We retrospectively analyzed the hematopoietic reconstitution, graft-versus-host disease (GVHD), and quality of life (QOL) in 56 patients with hematologic malignancies who underwent non-myeloablative stem cell transplantation (NST) with a conditioning regimen based on anti-thymocyte globulin (ATG), followed by donor lymphocyte infusion (n=24), or Fludarabine (FLU) (n=32). Hematopoietic stem cells were derived from low-resolution HLA-matched identical sibling donors. RESULTS: The blood type transformation and platelet reconstitution presented significantly earlier in the FLU group than the ATG group (P<0.05). Within 100 days post-transplantation, the incidence of grade I–IV acute GVHD was significantly lower in the ATG group than the FLU group (P<0.05). After 100 days post-transplant, extensive chronic GVHD (cGVHD) was more prevalent in the ATG group than the FLU group (P<0.05). There were lower cumulative risk of relapse and higher non-relapse-related mortality in the ATG group, but better QOL in the FLU group within 24 months, and no difference in 3-year disease-free survival (DFS) or overall survival (OS) between the 2 groups (P>0.05). CONCLUSIONS: The FLU-based conditioning regimen improved hematopoietic reconstitution and decreased extensive cGVHD, but there was no difference in 3-year DFS or OS between the 2 groups. International Scientific Literature, Inc. 2015-08-04 /pmc/articles/PMC4530985/ /pubmed/26238068 http://dx.doi.org/10.12659/MSM.893846 Text en © Med Sci Monit, 2015 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Clinical Research Li, Qingshan Meng, Fanyi Zhou, Ming Yu, Bizhen Mo, Wenjian Du, Qinghua Jiang, Xuejie Wei, Yaming Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title | Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title_full | Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title_fullStr | Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title_full_unstemmed | Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title_short | Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies |
title_sort | clinical comparison of non-myeloablative conditioning with anti-thymocyte globulin and fludarabine for patients with hematologic malignancies |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530985/ https://www.ncbi.nlm.nih.gov/pubmed/26238068 http://dx.doi.org/10.12659/MSM.893846 |
work_keys_str_mv | AT liqingshan clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT mengfanyi clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT zhouming clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT yubizhen clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT mowenjian clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT duqinghua clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT jiangxuejie clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies AT weiyaming clinicalcomparisonofnonmyeloablativeconditioningwithantithymocyteglobulinandfludarabineforpatientswithhematologicmalignancies |